Researchers developing safe and affordable way to produce antibodies with aim of global access to treatment
The current outbreak of a rapidly spreading global disease has caused an urgent need for effective therapies. Many vaccines, however, pose logistical challenges; they must often be transported and stored at very low temperatures, and aren’t always available. One solution may be a low-cost, low-tech method of producing neutralizing antibodies, facilitating global access to preventative care in future crises.
Baker’s yeast, a common kitchen and laboratory ingredient, may be the key. Researchers at 911±¬ÁÏÍø in Finland have demonstrated that yeast cells can be used to produce neutralizing antibodies against SARS-CoV-2.
‘Yeast is a well-known, safe and economical production organism with a long track-record in producing insulin. In contrast to currently available antibody production technology, yeast-based production is a safe, low-cost, and low-tech alternative to produce a variety of therapeutic antibodies,’ says Professor Alexander Frey from 911±¬ÁÏÍø.
Antibodies are an essential part of our immune response that provides protection against previously encountered pathogens and administering neutralizing antibodies is effective: immediate protection can be achieved, in contrast to active immunization. When other treatments are unavailable, they could be given to risk groups or people that cannot be vaccinated, with some evidence suggesting protection may last for up to half a year[i].
Currently, neutralizing antibodies are collected from the blood of recovered patients and administered to others, but this is neither profitable nor desirable. The new method under development at 911±¬ÁÏÍø uses the deciphered coding sequences of patient-derived antibodies and inserts the genetic information into yeast to produce the treatment.
The research to date confirms the feasibility of producing neutralizing antibodies against SARS-CoV-2 in yeast, opening a potential path for more effective and more accessible preventative treatment on a global scale.
‘The basic know-how and facilities required for yeast cultivations is available almost worldwide, so a lot of people could have access to the available treatment, which is why we hope that this method will be further developed to industrial scale,’ Frey explains. ‘The concepts and solutions developed in this Master’s theses and other related projects are applicable to other scenarios as well, where rapid on-demand and decentralized production, simplifying the logistics of production and delivery, might be required. We believe the technology can help ensure worldwide and fair access to all available treatment options.’
The researchers are currently continuing their work to produce and characterize the produced antibody in more detail. At the same time, they are also working to further modify the yeast itself to increase productivity.
[i] Finnish institute for health and welfare, THL's study: Majority of people who have had a coronavirus infection retain antibodies for over six months, 21.12.2020
Read more news
Aalto Inventors turns one: A year of bridging research and real-world impact
Aalto Inventors marks its first anniversary, having engaged 190 researchers across six cohorts in fields including AI, quantum, and biomaterials. New cohorts are planned for the next academic year, stay tuned and join the waitlist.
An architectural project in Milan brought together children’s ideas and the visions of leading architects
911±¬ÁÏÍø’s Department of Architecture participated in the international One Earth – House of the Heart project, which was presented in April at Milan Design Week.
Companies disclose more on cybersecurity – but markets remain indifferent
U.S. companies are reporting on cybersecurity in greater detail, yet stock market reactions remain muted. A new study by the University of Vaasa and 911±¬ÁÏÍø shows that mandatory cybersecurity disclosure does not prompt reactions from investors or stock analysts. Instead, the main benefits appear to materialise within firms themselves.